113 related articles for article (PubMed ID: 36764415)
1. Preparation of PEGylated nedaplatin liposomes with sustained release behavior for enhancing the antitumor efficacy of non-small cell lung cancer.
Tang J; Yang Z; Zhang Y; Huang R; Yu C; Yu C
Int J Pharm; 2023 Mar; 635():122708. PubMed ID: 36764415
[TBL] [Abstract][Full Text] [Related]
2. Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs.
Huang R; Chen H; Pi D; He X; Yu C; Yu C
Eur J Pharm Biopharm; 2024 May; 198():114239. PubMed ID: 38452907
[TBL] [Abstract][Full Text] [Related]
3. Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes.
Yi S; Zhang C; Hu J; Meng Y; Chen L; Yu H; Li S; Wang G; Zheng G; Qiu Z
AAPS PharmSciTech; 2021 Jan; 22(1):26. PubMed ID: 33404864
[TBL] [Abstract][Full Text] [Related]
4. PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer.
Li XT; Zhou ZY; Jiang Y; He ML; Jia LQ; Zhao L; Cheng L; Jia TZ
J Drug Target; 2015 Apr; 23(3):232-43. PubMed ID: 25417934
[TBL] [Abstract][Full Text] [Related]
5. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
6. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
[TBL] [Abstract][Full Text] [Related]
8. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma.
Kumar MR; Aithal BK; Udupa N; Reddy MS; Raakesh V; Murthy RS; Raju DP; Rao BS
Drug Deliv; 2011; 18(7):511-22. PubMed ID: 21793763
[TBL] [Abstract][Full Text] [Related]
9. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
[TBL] [Abstract][Full Text] [Related]
10. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes.
Andriyanov AV; Koren E; Barenholz Y; Goldberg SN
PLoS One; 2014; 9(5):e92555. PubMed ID: 24786533
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization and
Zare Kazemabadi F; Heydarinasab A; Akbarzadeh A; Ardjmand M
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3222-3230. PubMed ID: 31373225
[No Abstract] [Full Text] [Related]
14. Preparation, in vitro Characterization and Pharmacokinetic Study of Coenzyme Q10 Long-Circulating Liposomes.
Yang S
Drug Res (Stuttg); 2018 May; 68(5):270-279. PubMed ID: 29190857
[TBL] [Abstract][Full Text] [Related]
15. Preparation and
Wang F; Zhang G; Zang C; Pan H; Ma L; Li C; Hou H; Su P; Gao Y; Sun J; Ye Z
J Nanosci Nanotechnol; 2020 Apr; 20(4):2558-2566. PubMed ID: 31492276
[TBL] [Abstract][Full Text] [Related]
16. [Optimization of Formulation and Process of Paclitaxel PEGylated Liposomes by Box-Behnken Response Surface Methodology].
Shi YJ; Zhang XF; Guo QT
Zhong Yao Cai; 2015 Dec; 38(12):2606-10. PubMed ID: 27352544
[TBL] [Abstract][Full Text] [Related]
17. Oseltamivir phosphate loaded pegylated-Eudragit nanoparticles for lung cancer therapy: Characterization, prolonged release, cytotoxicity profile, apoptosis pathways and in vivo anti-angiogenic effect by using CAM assay.
Yurtdaş-Kırımlıoğlu G; Güleç K; Görgülü Ş; Kıyan HT
Microvasc Res; 2022 Jan; 139():104251. PubMed ID: 34520775
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.
Kala SG; Chinni S
Drug Deliv Transl Res; 2022 Nov; 12(11):2856-2864. PubMed ID: 35322372
[TBL] [Abstract][Full Text] [Related]
19. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha.
Vyas SP; Rawat M; Rawat A; Mahor S; Gupta PN
Drug Dev Ind Pharm; 2006 Jul; 32(6):699-707. PubMed ID: 16885125
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity.
Yalcin TE; Ilbasmis-Tamer S; Ibisoglu B; Özdemir A; Ark M; Takka S
Pharm Dev Technol; 2018 Jan; 23(1):76-86. PubMed ID: 28724327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
